Immunoglobulin chimeric monomer-dimer hybrids

Details Immunoglobulin chimeric monomer-dimer hybrids Immunoglobulin chimeric monomer-dimer hybrids

2008-03-25

2008-03-25

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C530S387100, C530S387300, C530S391700, C530S402000

Reexamination Certificate

active

11029003

ABSTRACT:
The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

REFERENCES:
patent: 3941763 (1976-03-01), Sarantakis
patent: 4695623 (1987-09-01), Stabinsky
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5162220 (1992-11-01), Oshima et al.
patent: 5175096 (1992-12-01), Hook et al.
patent: 5189015 (1993-02-01), Hook et al.
patent: 5234830 (1993-08-01), Oshima et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5482858 (1996-01-01), Huston et al.
patent: 5579277 (1996-11-01), Kelly
patent: 5585089 (1996-12-01), Queen et al.
patent: 5591573 (1997-01-01), Whalen et al.
patent: 5605689 (1997-02-01), Ammann
patent: 5648240 (1997-07-01), Hook et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5885821 (1999-03-01), Magota et al.
patent: 5910573 (1999-06-01), Pluckthun et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6015881 (2000-01-01), Kang et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6060065 (2000-05-01), Barney et al.
patent: 6060613 (2000-05-01), Hattori et al.
patent: 6068973 (2000-05-01), Barney et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6093799 (2000-07-01), Li et al.
patent: 6184344 (2001-02-01), Kent et al.
patent: 6228983 (2001-05-01), Barney et al.
patent: 6281331 (2001-08-01), Kang et al.
patent: 6310180 (2001-10-01), Tam
patent: 6310183 (2001-10-01), Johannessen et al.
patent: 6326468 (2001-12-01), Canne et al.
patent: 6329176 (2001-12-01), Woldike et al.
patent: 6469136 (2002-10-01), Bray et al.
patent: 6475491 (2002-11-01), Johnson et al.
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 6518013 (2003-02-01), Barney et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 2002/0081664 (2002-06-01), Lo et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2003/0180287 (2003-09-01), Gambotz et al.
patent: 2003/0235536 (2003-12-01), Blumberg et al.
patent: 2004/0077022 (2004-04-01), Feige et al.
patent: 2005/0027109 (2004-05-01), Mezo et al.
patent: 2005/0037941 (2004-05-01), Bitonti et al.
patent: 0 325 262 (1989-07-01), None
patent: 0 589 577 (1997-02-01), None
patent: 2 641 468 (1990-07-01), None
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/10134 (1989-11-01), None
patent: WO 90/11364 (1990-10-01), None
patent: WO 92/10209 (1992-06-01), None
patent: WO 93/11162 (1993-06-01), None
patent: WO 00/18881 (2000-05-01), None
patent: WO 01/02439 (2001-01-01), None
patent: WO 01/36637 (2001-05-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 01/91780 (2001-12-01), None
patent: WO 02/18417 (2002-03-01), None
patent: WO 02/46208 (2002-06-01), None
patent: WO 02/089828 (2002-11-01), None
patent: WO 03/077834 (2003-09-01), None
patent: WO 03/077834 (2003-09-01), None
patent: WO 2004/003176 (2004-01-01), None
patent: WO 2004/006962 (2004-01-01), None
patent: WO 2004/101740 (2004-11-01), None
patent: WO 2005/001025 (2005-01-01), None
US 6,020,459, 02/2000, Barney et al. (withdrawn)
Pontikaki et al. Side effects fo anti-TNFalpha therapy in juvenile idiopathic arthritis. Reumatismo 2006, vol. 58(1), pp. 31-38.
Stevenson et al. Conjugation of Human Fcy in Closed-Hinge or Open-Hinge Configuration to Fab'y and Analogous Ligands. The Journal of Immunology 1997, vol. 158, pp. 2242-2250.
Dargaud et al. Haemophilia therapies. Expert Opinions in Biological Therapies 2007, vol. 7, No. 5, pp. 651-663.
International Search Report for PCT/US04/14064 dated Apr. 6, 2006.
U.S. Appl. No. 10/841,819, filed May 6, 2004, Rivera et al.
U.S. Appl. No. 10/841,956, filed May 6, 2004, Hehir et al.
Armour et al., “Recombinant human IgG molecules lacking Fcy receptor I binding and monocyte triggering activities,”Eur. J. Immunol., 29:2613-2624 (1999).
Bahimann, Ferdinand H. et al., “Erythropoietin: is it more than correcting anaemia?,”Nephrol. Dial. Transplant., 19:20-22 (2004).
Barre-Sinoussi et al., “Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS),”Science, 220:868-871 (1983).
Burmeister et al., “Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor,”Nature, 372:323-324 (1994).
Friend et al., “Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection,”Transplantation, 68:1632-1637 (1999).
Gallo et al., “Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS,”Science, 224:500-503 (1984).
Israel et al., “Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells,”Immunol., 92:69-74 (1997).
Johannessen et al., “Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven®),”Blood Coagul. Fibrinolysis, 11 Suppl. 1:S159-S164 (2000).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse ,”Nature, 321:522-525 (1986).
Kang et al., “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces,”Proc. Natl. Acad. Sci. USA, 88:4363-4366 (1991).
Kobayashi et al., “FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells,”Am. J. Physiol. Renal Physiol., 282:F358-F365 (2002).
Lemaitre et al., “Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA Initiation site,”Proc. Natl. Acad. Sci. USA, 84:648-652 (1987).
Letsinger et al., “Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture,”Proc. Natl. Acad. Sci. USA, 86:6553-6536 (1989).
Mark et al., “By-passing immunization: Building high affinity antibodies by chain shuffling,”Bio/Technol., 10:779-783 (1992).
McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains,”Nature, 348:552-554 (1990).
Meer, P., et al., “Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury,”Eur. J. Heart Fail., 6(7):853-859 (2004).
Nussbaum et al., “Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation,”J. Virol., 68(9):5411-5422 (1994).
Rossi, “Making ribozymes work in cells,”Curr. Biol., 4:469-471 (1994).
Routledge et al., “The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody,”Transplantation, 60:847-853 (1995).
Sarver et al., “Ribozymes as potential anti-HIV-1 therapeutic agents,”Science, 247:1222-1225 (1990).
Shields et al., “High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of Ig

Affiliated with

Also associated with

Rating

Immunoglobulin chimeric monomer-dimer hybrids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoglobulin chimeric monomer-dimer hybrids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoglobulin chimeric monomer-dimer hybrids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3930769